ArticleCase reports in ophthalmology
Place of New Anti-Vascular Endothelial Growth Factor Agents in Recalcitrant Radiation Maculopathy: Case Reports.
Article in Case reports in ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Anti-vascular endothelial growth factor (VEGF) therapy is the main treatment alternative in radiation maculopathy as it reduces the macular edema and thereby improves the vision to some extent. The efficacy of newer-generation anti-VEGF agents with greater durability is less known in this entity. This report highlights the administration of faricimab and 8 mg aflibercept in the management of two recalcitrant cases. Case Presentations: We report two cases with radiation retinopathy following the CyberKnife stereotactic radiotherapy for the treatment of choroidal melanoma. A 25-year-old man developed left radiation retinopathy 8 months after the treatment. Though three consecutive posterior subtenon 20 mg triamcinolone acetonide injections within 20 months, followed by two intravitreal 1.25 mg bevacizumab injections together with scatter peripheric laser treatment within 8 months, were given, there was persistent severe macular edema, peripheral retinal ischemia, and retinal neovascularizations (NVEs). He was then treated at our department with seven monthly intravitreal faricimab injections, one subsequent aflibercept 8 mg injection, and additional scatter laser photocoagulation, resulting in modest visual improvement, decreased macular edema, and disappearance of NVEs. The second case was a 35-year-old woman diagnosed with radiation retinopathy 1 year after the treatment for the right uveal melanoma. Despite two posterior subtenon 20 mg triamcinolone acetonide injections performed within 11 months, maculopathy was worsened, and she was treated sequentially with four monthly faricimab and five monthly 8 mg aflibercept injections. Macular edema improved partially, and she experienced some visual improvement. Conclusion: Despite administering more durable agents (faricimab and aflibercept 8 mg) even monthly, there were modest anatomical and visual improvements in both cases with recalcitrant radiation maculopathy. Our observations were preliminary clinical observations, rather than definitive evidence, regarding the efficacy of faricimab and aflibercept 8 mg in radiation maculopathy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.